活血化瘀药在冠心病中现代临床应用
|
摘要
近年来我国冠心病患者数量逐年增多,冠心病是临床上最常见的疾病之一。血瘀是导致冠心病的重要发病因素,在发病过程中占据主要的位置。从古至今的诸多医家对于血瘀而导致的冠心病均有独到的见解。近年来活血化瘀药物是治疗冠心病的常用药物,具有非常显著地疗效,广泛应用在眼科、神经科、内分泌科中。该文主要讨论了使用活血化瘀药物治疗冠心病的理论依据、现代对血瘀与冠心病关系的认识及常用的活血化瘀药。
In recent years,the number of patients with coronary heart disease is increasing year by year,and coronary heart disease is one of the most common diseases in clinical practice. Blood stasis is an important pathogenic factor of coronary heart disease,which occupies a major position in the course of the disease. Many physicians from ancient times to the present have unique views on coronary heart disease caused by blood stasis. In recent years,the drugs of activating blood circulation and removing blood stasis are commonly used in the treatment of coronary heart disease. In addition,these drugs have very significant curative effect and are widely used in ophthalmology,neurology and endocrinology. This article mainly discusses the theoretical basis of using blood-activating and stasis-removing drugs to treat coronary heart disease,modern understanding of the relationship between blood stasis and coronary heart disease,and commonly used drugs for promoting blood circulation and stasis-removing.
In recent years,the number of patients with coronary heart disease is increasing year by year,and coronary heart disease is one of the most common diseases in clinical practice. Blood stasis is an important pathogenic factor of coronary heart disease,which occupies a major position in the course of the disease. Many physicians from ancient times to the present have unique views on coronary heart disease caused by blood stasis. In recent years,the drugs of activating blood circulation and removing blood stasis are commonly used in the treatment of coronary heart disease. In addition,these drugs have very significant curative effect and are widely used in ophthalmology,neurology and endocrinology. This article mainly discusses the theoretical basis of using blood-activating and stasis-removing drugs to treat coronary heart disease,modern understanding of the relationship between blood stasis and coronary heart disease,and commonly used drugs for promoting blood circulation and stasis-removing.
引文
[1]熊旭东.内科学[M].上海:上海科学技术出版社,2006:142.
[2]王聪霞,范雅洁.冠心病血管内皮损伤与血管重构的研究进展[J].西安交通大学学报(医学版),2018,39(4):455-458.
[3]刘龙涛,陈可冀,付长庚,等.从“因瘀致毒”谈冠心病的病因病机[J].中国中西医结合杂志,2015,35(11):1378-1380.
[4]王永刚,齐婧,钟伟,等.冠心病中医病因病机的认识与探索[J].中医杂志,2015,56(17):1449-1452.
[5]刘梅.丹红注射液治疗心绞痛心血瘀阻证疗效观察[J].中国中医急症,2007,16(11):1325.
[6]段练,熊兴江,王阶.冠心病的治疗性血管新生与活血化瘀[J].中国中西医结合杂志,2013,33(11):1561-1566.
[7]史大卓.陈可冀院士冠心病病证结合治疗方法学的创新和发展[J].中国中西医结合杂志,2011,31(8):1017-1020.
[8]秦建国,翁维良,郭维琴.郭士魁学术思想探析[J].中医杂志,2015,56(15):1273-1275.
[9]李秋艳,王辉,张东,等.翁维良活血化瘀治疗冠心病用药特点[J].中国中医基础医学杂志,2011,17(4):398,403.
[10]代升平,朱翠玲.朱翠玲治疗冠心病经验[J].辽宁中医杂志,2009,36(4):519-520.
[11]段练,熊兴江,王阶.冠心病的治疗性血管新生与活血化瘀[J].中国中西医结合杂志,2013,33(11):1561-1566.
[12]陈晨,刘倩,高华.活血化瘀药药理作用研究进展[J].中国药事,2011,25(6):603-605.
[12]朱通会.活血化瘀药的药理分析[J].中国社区医师(综合版),2005(13):8-9.
[13]周尹轶凡,李益萍,高俊杰,等.活血化瘀类中药抗血小板作用机制研究进展[J].中成药,2018,40(3):659-662.
[14]袁淑娟,张志伟,高天红,等.红花注射液抗血栓作用机制研究[J].中国中药杂志,2011,36(11):1528-1529.
[15]牛贝贝,张群娣,崔秋燕,等.活血化瘀法运用于心血管疾病之现状[J].中医药导报,2009,15(1):84-86.
[16]李青融,王子妤.三七总皂苷药理作用的研究进展[J].湖南中医杂志,2017,33(9):216-218.
[17]李源,段红,王天成,等.川芎嗪对再灌注大鼠心肌细胞c-fos基因表达及凋亡的影响[J].心脏杂志,2000(3):213-215.
[18]李霁,王阶,王师菡,等.凋亡因子在冠心病中的作用及活血化瘀药对其干预的影响[J].中国中医基础医学杂志,2008(4):280-282.
[19]黄素芳,侯如艳,高烁烁,等.治疗冠心病中药使用频率的研究分析[J].中药新药与临床药理,2009,20(4):395-396.
[20]陈磊,陆茵,郑仕中.丹参药理活性成分的整合效应[J].中草药,2009,40(3):476-479.
[21]陈芬燕,郭韧,张毕奎.丹参酮Ⅱ_A的心血管药理作用研究进展[J].中国中药杂志,2015,40(9):1649-1653.
[22]高丽娜,崔元璐,延阔,等.丹参红花配伍研究进展[J].中草药,2016,47(4):671-679.
[23]李秋怡,干国平,刘焱文.川芎的化学成分及药理研究进展[J].时珍国医国药,2006(7):1298-1299.
[24]黎帆,余克花,莫冰,等.川芎嗪对CVB3感染小鼠心肌细胞凋亡的影响[J].南昌大学学报(医学版),2010,50(4):14-16.
[25]刘金柱,王铁,赵远贵,等.丹参川芎嗪注射液对老年不稳定型心绞痛患者的疗效和对血清hs-CRP、血脂的影响[J].中药药理与临床,2015,31(4):237-239.
[26]施峰,刘焱文.红花的化学成分及药理研究进展[J].时珍国医国药,2006(9):1666-1667.
[27]郑昌柱,鲜玉琼,陈静,等.红花注射液对冬眠心肌血运重建的临床研究[J].中国中药杂志,2014,39(7):1311-1314.
[28]徐东明,金晔,徐伟平.红花注射液治疗稳定型心绞痛[J].中国新药与临床杂志,2003(1):13-15.
[29]赵永见,牛凯,唐德志,等.桃仁药理作用研究近况[J].辽宁中医杂志,2015,42(4):888-890.
[30]彭放,邢杨波,唐伟良,等.桃仁、红花不同配比的血府逐瘀汤后处理对缺血再灌注心肌保护的临床研究[J].中华中医药学刊,2013,34(4):783.
[2]王聪霞,范雅洁.冠心病血管内皮损伤与血管重构的研究进展[J].西安交通大学学报(医学版),2018,39(4):455-458.
[3]刘龙涛,陈可冀,付长庚,等.从“因瘀致毒”谈冠心病的病因病机[J].中国中西医结合杂志,2015,35(11):1378-1380.
[4]王永刚,齐婧,钟伟,等.冠心病中医病因病机的认识与探索[J].中医杂志,2015,56(17):1449-1452.
[5]刘梅.丹红注射液治疗心绞痛心血瘀阻证疗效观察[J].中国中医急症,2007,16(11):1325.
[6]段练,熊兴江,王阶.冠心病的治疗性血管新生与活血化瘀[J].中国中西医结合杂志,2013,33(11):1561-1566.
[7]史大卓.陈可冀院士冠心病病证结合治疗方法学的创新和发展[J].中国中西医结合杂志,2011,31(8):1017-1020.
[8]秦建国,翁维良,郭维琴.郭士魁学术思想探析[J].中医杂志,2015,56(15):1273-1275.
[9]李秋艳,王辉,张东,等.翁维良活血化瘀治疗冠心病用药特点[J].中国中医基础医学杂志,2011,17(4):398,403.
[10]代升平,朱翠玲.朱翠玲治疗冠心病经验[J].辽宁中医杂志,2009,36(4):519-520.
[11]段练,熊兴江,王阶.冠心病的治疗性血管新生与活血化瘀[J].中国中西医结合杂志,2013,33(11):1561-1566.
[12]陈晨,刘倩,高华.活血化瘀药药理作用研究进展[J].中国药事,2011,25(6):603-605.
[12]朱通会.活血化瘀药的药理分析[J].中国社区医师(综合版),2005(13):8-9.
[13]周尹轶凡,李益萍,高俊杰,等.活血化瘀类中药抗血小板作用机制研究进展[J].中成药,2018,40(3):659-662.
[14]袁淑娟,张志伟,高天红,等.红花注射液抗血栓作用机制研究[J].中国中药杂志,2011,36(11):1528-1529.
[15]牛贝贝,张群娣,崔秋燕,等.活血化瘀法运用于心血管疾病之现状[J].中医药导报,2009,15(1):84-86.
[16]李青融,王子妤.三七总皂苷药理作用的研究进展[J].湖南中医杂志,2017,33(9):216-218.
[17]李源,段红,王天成,等.川芎嗪对再灌注大鼠心肌细胞c-fos基因表达及凋亡的影响[J].心脏杂志,2000(3):213-215.
[18]李霁,王阶,王师菡,等.凋亡因子在冠心病中的作用及活血化瘀药对其干预的影响[J].中国中医基础医学杂志,2008(4):280-282.
[19]黄素芳,侯如艳,高烁烁,等.治疗冠心病中药使用频率的研究分析[J].中药新药与临床药理,2009,20(4):395-396.
[20]陈磊,陆茵,郑仕中.丹参药理活性成分的整合效应[J].中草药,2009,40(3):476-479.
[21]陈芬燕,郭韧,张毕奎.丹参酮Ⅱ_A的心血管药理作用研究进展[J].中国中药杂志,2015,40(9):1649-1653.
[22]高丽娜,崔元璐,延阔,等.丹参红花配伍研究进展[J].中草药,2016,47(4):671-679.
[23]李秋怡,干国平,刘焱文.川芎的化学成分及药理研究进展[J].时珍国医国药,2006(7):1298-1299.
[24]黎帆,余克花,莫冰,等.川芎嗪对CVB3感染小鼠心肌细胞凋亡的影响[J].南昌大学学报(医学版),2010,50(4):14-16.
[25]刘金柱,王铁,赵远贵,等.丹参川芎嗪注射液对老年不稳定型心绞痛患者的疗效和对血清hs-CRP、血脂的影响[J].中药药理与临床,2015,31(4):237-239.
[26]施峰,刘焱文.红花的化学成分及药理研究进展[J].时珍国医国药,2006(9):1666-1667.
[27]郑昌柱,鲜玉琼,陈静,等.红花注射液对冬眠心肌血运重建的临床研究[J].中国中药杂志,2014,39(7):1311-1314.
[28]徐东明,金晔,徐伟平.红花注射液治疗稳定型心绞痛[J].中国新药与临床杂志,2003(1):13-15.
[29]赵永见,牛凯,唐德志,等.桃仁药理作用研究近况[J].辽宁中医杂志,2015,42(4):888-890.
[30]彭放,邢杨波,唐伟良,等.桃仁、红花不同配比的血府逐瘀汤后处理对缺血再灌注心肌保护的临床研究[J].中华中医药学刊,2013,34(4):783.